Friday, April 6, 2018 News Recap: HCV – Liver Cancer (HCC): Liver Cancer on the Rise in Backdrop of Undiagnosed Hep C. Liver cancer, one of the greatest challenges to hepatologists today, will be in the spotlight at the upcoming International Liver Congress (ILC) 2018. It will become an even greater challenge in the near future, said Morris Sherman, PhD, from the University of Toronto, who is chair of the Canadian Liver Foundation. Testing for he...
A Conatus Pharmaceuticals drug developed as a treatment for chronic liver disease has failed to beat a placebo in a mid-stage study, the first of four underway for the drug. Conatus (NASDAQ: CNAT) tested its drug, emricasan, in liver transplant patients whose hepatitis C virus has cleared, but who still have fibrosis or cirrhosis in the transplanted organ. The drug is meant to reduce the activity of enzymes that play a role in inflammation and cell death.
Targeting Chronic Hepatitis B Infections Affecting More Than 240 Million People Worldwide. ATLANTA, GA, Feb. 07, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that it is collaborating with CaroGen Corporation on the development of a combination immunotherapy treatment for chronic hepatitis B virus (HBV) infection. The project will include testing GeoVax’s MVA-VLP-HBV (Modified
Chronic Hepatitis B, a currently incurable disease, is attracting growing attention among international biotechs. The World Health Organisation estimates 257 million people live with Hep B and up to 900,000 die each year from related diseases such as liver cancer and cirrhosis. In Australia, more than 232,000 people have chronic hepatitis B, according to lobby group Hepatitis Australia. “Deaths from primary liver cancer have been climbing faster tha
Friday, October 6, 2017 News Recap: Liver Cancer Two studies on liver cancer in the news last week highlighted the global prevalence and causes of this terrible disease. The first showed a direct correlation between excess weight and cancer occurrence (including liver cancer) – Cancers linked to excess weight make up 40% of all US diagnoses, study finds, while the second focussed on the global incidence of primary liver cancer. Hepatitis B virus wa...
With hepatitis C virus starting to look like a conquered foe, attention is turning to the fight against chronic hepatitis B virus (HBV), and Vivek Ramaswamy’s Roivant has just put another sizable block of cash behind a program in development at Canada’s Arbutus Biopharma. The $116 million share purchase deal comes on the heels of positive phase 2 data for Arbutus’ lead HBV candidate ARB-1467, which suggest the gene-silencing drug can further reduce hepati
Friday, September 15, 2017 News Recap: President’s Report from HepCBC’s Annual General Meeting (AGM) HepCBC held its Annual General Meeting on September 12, 2017, and we are pleased to note that all the issues that we needed to address were covered. Rosemary Plummer has stepped down as president after 2 GREAT YEARS of service, but the rest of the Board of Directors has been re-elected, and some very important changes to our Constitution and Bylaws ...
Citing a crowded market of innovative meds, Janssen has canned work on its hep C cocktail program with partners Medivir and Achillion. The pair were working on the hepatitis C treatment regimen known as JNJ-4178, a combo of three direct acting antivirals: AL-335, Achillion’s odalasvir and the Janssen-Medivir med Olysio (simeprevir). The Big Pharma said that the ongoing phase 2 tests with JNJ-4178 will be completed as planned, “but there will be no additio
Regulus Therapeutics Inc. (RGLS) said the U.S. Food and Drug Administration (FDA) is maintaining a clinical hold on its hepatitis C drug candidate, RG-101. The drug was placed on clinical hold in June 2016, when a second case of jaundice was reported during clinical trials. FDA Requests More Data Although Regulus submitted a response following the clinical hold last summer, the FDA has requested final safety and efficacy data from an ongoing clinical tri
Timelines of On-going Studies are not Expected to be Impacted Conference Call Today at 5:00 p.m. ET LA JOLLA, Calif., June 27, 2016 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced it received verbal notice from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) for RG-101 for the t